Saturday, December 12, 2020 12:14:35 PM
Aytu’s existing portfolio includes a nasal testosterone spray for men, a spray sleep aid and a 12-hour codeine-based cough syrup. Its pediatric products range from antibiotics and allergy medication to supplements for infants and children with fluoride deficiency.
It also distributes COVID-19 rapid antibody and antigen tests, and recently licensed rights to develop an ultraviolet medical device as a treatment for the coronavirus and other respiratory infections. In addition, Aytu operates a consumer health subsidiary, Innovus Pharmaceuticals Inc., that develops and sells men’s and women’s health and vitality products direct to consumers.
Dec 10, 2020
https://www.dallasnews.com/business/health-care/2020/12/10/grand-prairie-based-neos-therapeutics-is-merging-with-a-colorado-specialty-pharma-company/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM